SCHEMBL13629401

SCHEMBL13629401

CCc1ccc(NS(=O)(=O)c2cccc(Cl)c2Cl)cc1C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.65
PGR P06401 1/20 0.52
LMNA P02545 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
THRB P10828 1/20 0.50
HPGD P15428 1/20 0.50
PTGES2 Q9H7Z7 3/20 0.49
GHSR Q92847 1/20 0.48
WDR5 P61964 1/20 0.47
BRD4 O60885 1/20 0.46
SLC22A12 Q96S37 2/20 0.46
CCR4 P51679 1/20 0.46
HSD17B1 P14061 1/20 0.45
HSD17B2 P37059 1/20 0.45
PKM P14618 1/20 0.45
CDK1 P06493 1/20 0.45
CCNB1 P14635 1/20 0.45
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13852948 0.89 ALDH1A1 (0.61) ALDH1A1PGRLMNAMEN1KMT2A
SCHEMBL13629320 0.89 SLC22A12 (0.54) ALDH1A1PGRLMNAMEN1KMT2A
SCHEMBL13629312 0.86 ALDH1A1 (0.58) ALDH1A1PGRLMNAMEN1KMT2A
SCHEMBL13629424 0.85 ALDH1A1 (0.62) ALDH1A1PGRLMNAMEN1KMT2A
SCHEMBL13629415 0.82 MEN1 (0.57) ALDH1A1LMNAMEN1KMT2ABRD4
SCHEMBL13615029 0.82 ALDH1A1 (0.59) ALDH1A1PGRLMNAMEN1KMT2A
SCHEMBL13629279 0.81 PGR (0.60) ALDH1A1PGRLMNAMEN1KMT2A
SCHEMBL13629329 0.80 ALDH1A1 (0.65) ALDH1A1LMNAHPGDCDK1CCNB1
SCHEMBL16325865 0.80 ALDH1A1 (0.63) ALDH1A1PGRLMNAMEN1KMT2A
SCHEMBL13875335 0.79 PGR (0.65) ALDH1A1PGRLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2121/4885PGR 1648/4885LMNA 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.